Product Images Metformin Hydrochloride

The table summarizes the percentage of changes observed in cholesterol levels in patients taking three different dosages of metformin hydrochloride over 24 weeks. The table shows the mean percent change of Total Cholesterol, Total Triglycerides, LDL-Cholesterol, and HDL-Cholesterol levels from the baseline at the time of the final visit. The number of participants in each group is also mentioned in the table.*

The table displays the mean changes from baseline in Hemoglobin Ay, Fasting Plasma Glucose, and Body Weight at Week 12 and final visit (24-week study) for Metformin Hydrochloride Extended Release Tablets in doses of 500mg, 1000mg, and 1500mg, taken twice daily or once daily, on patients with diabetes. The baseline and changes at the week 12 and the final visit are shown for all the measurements. The number of patients in each group is also mentioned.*

This is a table summarizing the percent change from the baseline of major serum lipid variables in patients who completed 29-week studies. The table compares the effects of Metformin Hydrochloride Tablets and Placebo as well as their combined effect with Glyburide monotherapy. The percent change from baseline is shown for Total Cholesterol, Total Triglycerides, LDL-Cholesterol, and HDL-Cholesterol.*

This is a pharmaceutical label from NuCare Pharmaceuticals. It includes details such as NDC, AWP, Lot#, and expiration date for Metformin HCl tablets of strength 850mg. The label also includes a warning to keep the tablets out of reach of children and store at controlled temperature. However, some characters are not readable due to poor quality.*

This text provides information on a pediatric patient group with a mean age of 13.8 years and a range of 10 to 16 years. All patients were on a diet therapy at baseline, and there was not a statistically significant difference observed.*

This is a summary of the mean changes from baseline in fasting plasma glucose, HbA, and body weight for Metformin Hydrochloride Tablets vs Placebo after a 29-week study. The table presents results for FPG, Hemoglobin A, and Body Weight, along with baseline data for both groups. The table also shows the changes after the final visit in each category. For FPG, the change was significant, reducing by 530 mg/dL in those who took Metformin Hydrochloride Tablets, while in the Placebo group, it barely reduced by 63 mg/dL. Similarly, for Hemoglobin A, those taking Metformin Hydrochloride Tablets resulted in a significant 14% change, while Placebo group barely recorded a 4% change. And finally, there was no significant change in body weight in either group at the Final visit. It is noteworthy that all the participants were on diet therapy at Baseline.*

Table 10 shows the comparison between the effects of Metformin Hydrochloride Tablets and placebo in Pediatrics, specifically in terms of mean changes in plasma glucose and body weight at the final visit. The table presents the baseline measurements and the changes observed in both parameters, with statistical significance indicated by the p-value. The results suggest that Metformin Hydrochloride Tablets led to a significantly greater reduction in plasma glucose levels compared to placebo. However, there was no significant difference in body weight changes between the two groups.*

The text provides a summary of the mean changes from baseline in fasting plasma glucose, HbA, and body weight, at final visit for a 23-week study comparing the effects of combined metformin hydrochloride and glyburide tablets to glyburide or metformin hydrochloride tablets alone. The results are presented in Table 3, including the number of patients in each group and p-values for each comparison. There were no statistically significant differences observed between the treatments for fasting plasma glucose and body weight. However, there were statistically significant differences observed in HbA between the groups.*

The table presents a comparison between Metformin Hydrochloride Tablets/Insulin combination and Placebo insulin in terms of mean changes from baseline in Hemoglobin A1c and daily insulin dose. The data consists of mean values of these factors at Baseline and the Final visit, along with their Standard Error values. The treatment difference between the two is also shown. There is a statistically significant difference for Hemoglobin A1c when baseline is used as a covariate. However, the analysis of variance does not show any significant values. The insulin alone also showed significant results.*